drugset / Trial / NCT06262776
Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients
Recruiting
160 enrolled
Central Adelaide Local Health Network Incorporated
National Health and Medical Research Council, Australia · collabRoyal Prince Alfred Hospital, Sydney, Australia · collabUniversity of Adelaide · collab
NaSingle-groupOpen-labelPrevention
Summary
The goal of this clinical trial is to compare responses to Varicella Zoster vaccination between transplant patients on different medication regimens, and their healthy co-habitants. The main questions it aims to answer are: 1. Are there differences in vaccination immunological responses in transplant patients on different immunosuppression regimens? 2. Are there differences in vaccination immunological responses between transplant patients and their healthy co-habitants? Participants will all receive a 2-dose course of SHINGRIX recombinant Zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination.
Timeline
- Start
- 2024-03-20
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | Vaccine | 0.5 ml | Intramuscular |